AbbVie says FDA approves Skyrizi for ulcerative colitis

By Finance News on June 19, 2024

AbbVie said that the heavily-advertised drug was now approved for four conditions across different so-called “immune-mediated” inflammatory diseases.

Read More: AbbVie says FDA approves Skyrizi for ulcerative colitis

Markets

Comments (0)

Add Comment

AbbVie says FDA approves Skyrizi for ulcerative colitis

Related Posts

Warhammer maker Games Workshop says profits to top forecasts

Montreal fashion brand Groupe Dynamite launches IPO on Toronto Stock

The last time inflation was projected to get worse, this investment was

Tom’s of Maine toothpaste tainted with bacteria, says U.S. Food and Drug

Target CEO says ‘consumers continue to spend cautiously’ amid triple-miss

Why politicians and industry groups are calling Mexico a ‘back door’ for

Here’s how options traders are playing Nvidia in advance of its earnings